Biomaterial-based Treatments for Ocular Conditions
Synakis is a pre-clinical biotech startup developing biomaterial-based treatments for ocular injuries and diseases, including retinal detachment and glaucoma. Our mission is to improve the lives of patients suffering from these conditions.
Synakis’ core technology is a novel hydrogel biomaterial specifically designed for ocular delivery. Our biomaterial is injectable, biocompatible, biodegradable, non-swelling and transparent. We are developing it as a vitreous substitute for vitreoretinal surgery and to deliver engineered therapeutics to treat leading causes of blindness.
Synakis co-founders Mickael Dang, Adam Forman, and Jonathan Labriola with the Desjardins Startup Prize $40,000 1st place cheque.
Upcoming Events
Want to learn more about Synakis or meet our team? Catch us at these exciting upcoming events!